Search

Your search keyword '"Karim-Kos, Henrike E."' showing total 173 results
Start Over Author "Karim-Kos, Henrike E."
173 results on '"Karim-Kos, Henrike E."'

1. The survival disparity between children and adolescents and young adults (AYAs) with Ewing sarcoma in the Netherlands did not change since the 1990s despite improved survival: A population-based study

Author

Schulpen, Maya, Haveman, Lianne M., van der Heijden, Lizz, Kaal, Suzanne E.J., Bramer, Jos A.M., Fajardo, Raquel Dávila, de Haan, Jacco J., Hiemcke-Jiwa, Laura S., ter Horst, Simone A.J., Jutte, Paul C., Schreuder, Hendrik W.B., Tromp, Jacqueline M., van der Graaf, Winette T.A., van de Sande, Michiel A.J., Gelderblom, Hans, Merks, Johannes H.M., and Karim-Kos, Henrike E.

Published
2024
Full Text
View/download PDF

5. Incidence, survival, and mortality of cancer in children and young adolescents in Belgium and the Netherlands in 2004–2015: A comparative population‐based study.

Author

Peirelinck, Hanne, Schulpen, Maya, Hoogendijk, Raoull, Van Damme, An, Pieters, Rob, Henau, Kris, Van Damme, Nancy, and Karim‐Kos, Henrike E.

Subjects
CHILDHOOD cancer, CHILD mortality, CENTRAL nervous system tumors, CANCER-related mortality, NEUROBLASTOMA, TEENAGERS, AGE groups
Abstract

International comparisons of cancer surveillance measures may provide insight into inequalities in registration practices, etiological factors, and treatment strategies. This study aimed to compare incidence, survival, and mortality of cancer in children and young adolescents between Belgium and the Netherlands. All children (0–14 years) and young adolescents (15–17 years) diagnosed with cancer between 2004 and 2015 were selected from the population‐based cancer registries of Belgium (N = 4739) and the Netherlands (N = 7322). Differences in incidence and mortality were expressed as standardized rate ratios (SRR; BE/NL). Five‐year observed survival was calculated using the Kaplan–Meier method. During 2004–2015, the overall cancer incidence among children and young adolescents was similar in both countries. Incidence of neuroblastoma was significantly higher in Belgian children (2010–2015: SRR = 1.3, 95% CI 1.0–1.6). Five‐year survival of all malignant cancers was comparable in 2010–2015, exceeding 80% in both age groups. Remarkable differences in survival existed in children for malignant central nervous system (CNS) tumors in 2004–2009 (BE = 62%, NL = 45%), for acute myeloid leukemia (BE = 68%, NL = 78%) and rhabdomyosarcomas (BE = 60%, NL = 79%) in 2010–2015, and for neuroblastoma in both periods (2004–2009: BE = 76%, NL = 64%; 2010–2015: BE = 82%, NL = 64%). Overall cancer mortality in children decreased by approximately 3 percent‐points annually in both countries, but was slightly lower in Belgium in 2004–2009 (SRR = 0.9, 95% CI 0.7–1.0). Despite differences for specific cancer types, overall cancer incidence, survival, and mortality were comparable between Dutch and Belgian children and young adolescents in 2010–2015. Variability in screening, diagnosis, and registration practices probably explains the observed differences in incidence and survival of neuroblastoma and malignant CNS tumors. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Malignant extracranial germ cell tumors in the Netherlands between 1990-2018: stable incidence and improved survival

Author

Hulsker, Caroline C C, primary, Schulpen, Maya, additional, Mavinkurve-Groothuis, Annelies M C, additional, Visser, Otto, additional, Zsiros, József, additional, Wijnen, Marc H W, additional, de Krijger, Ronald R, additional, Bruggink, Annette H, additional, Looijenga, Leendert H J, additional, Karim-Kos, Henrike E., additional, and van der Steeg, Alida F W, additional

Published
2024
Full Text
View/download PDF

8. Survival disparities between children and adolescents and young adults for the major subtypes of non-Hodgkin lymphoma in the Netherlands: a large population-based study

Author

Schulpen, Maya, primary, Beishuizen, Auke, additional, Chamuleau, Martine E. D., additional, Dinmohamed, Avinash G., additional, Meyer-Wentrup, Friederike A. G., additional, Vormoor, H. Josef, additional, Van der Wagen, Lotte E., additional, Minnema, Monique C., additional, Loeffen, Jan L. C., additional, and Karim-Kos, Henrike E., additional

Published
2023
Full Text
View/download PDF

9. Impact of the COVID‐19 pandemic on paediatric renal tumour presentation and management, a SIOP renal tumour study group study

Author

Roy, Prakriti, primary, van Peer, Sophie E., additional, Dandis, Rana, additional, Duncan, Catriona, additional, de Aguirre‐Neto, Joaquim Caetano, additional, Verschuur, Arnauld, additional, de Camargo, Beatriz, additional, Karim‐Kos, Henrike E., additional, Boschetti, Luna, additional, Spreafico, Filippo, additional, Ramirez‐Villar, Gema L., additional, Graf, Norbert, additional, van Tinteren, Harm, additional, Pritchard‐Jones, Kathy, additional, and van den Heuvel‐Eibrink, Marry M., additional

Published
2023
Full Text
View/download PDF

13. Opposite Incidence Trends for Differentiated and Medullary Thyroid Cancer in Young Dutch Patients over a 30-Year Time Span (vol 13, 5104, 2021)

Author

Lebbink, Chantal A., van den Broek, Medard F. M., Kwast, Annemiek B. G., Derikx, Joep P. M., Dierselhuis, Miranda P., Kruijff, Schelto, Links, Thera P., van Trotsenburg, A. S. Paul, Valk, Gerlof D., Vriens, Menno R., Verrijn Stuart, Annemarie A., van Santen, Hanneke M., Karim-Kos, Henrike E., Guided Treatment in Optimal Selected Cancer Patients (GUTS), and Damage and Repair in Cancer Development and Cancer Treatment (DARE)

Published
2022

14. Correction: Lebbink et al. Opposite Incidence Trends for Differentiated and Medullary Thyroid Cancer in Young Dutch Patients over a 30-Year Time Span. Cancers 2021, 13, 5104

Author

Lebbink, Chantal A., primary, van den Broek, Medard F. M., additional, Kwast, Annemiek B. G., additional, Derikx, Joep P. M., additional, Dierselhuis, Miranda P., additional, Kruijff, Schelto, additional, Links, Thera P., additional, van Trotsenburg, A. S. Paul, additional, Valk, Gerlof D., additional, Vriens, Menno R., additional, Verrijn Stuart, Annemarie A., additional, van Santen, Hanneke M., additional, and Karim-Kos, Henrike E., additional

Published
2022
Full Text
View/download PDF

21. Progress against non-Hodgkin's lymphoma in children and young adolescents in the Netherlands since 1990: Stable incidence, improved survival and lower mortality

Author

Reedijk, Ardine M.J., primary, Beishuizen, Auke, additional, Coebergh, Jan Willem W., additional, Hoeben, Bianca A.W., additional, Kremer, Leontien C.M., additional, Hebeda, Konnie M., additional, Pieters, Rob, additional, Loeffen, Jan L.C., additional, and Karim-Kos, Henrike E., additional

Published
2022
Full Text
View/download PDF

22. Characteristics and outcome of children with renal tumors in the Netherlands: The first five-year’s experience of national centralization

Author

Roy, Prakriti, primary, van Peer, Sophie E., additional, de Witte, Martin M., additional, Tytgat, Godelieve A. M., additional, Karim-Kos, Henrike E., additional, van Grotel, Martine, additional, van de Ven, Cees P., additional, Mavinkurve-Groothuis, Annelies M. C., additional, Merks, Johannes H. M., additional, Kuiper, Roland P., additional, Hol, Janna A., additional, Janssens, Geert O. R., additional, de Krijger, Ronald R., additional, Jongmans, Marjolijn C. J., additional, Drost, Jarno, additional, van der Steeg, Alida F. W., additional, Littooij, Annemieke S., additional, Wijnen, Marc H. W. A., additional, van Tinteren, Harm, additional, and van den Heuvel-Eibrink, Marry M., additional

Published
2022
Full Text
View/download PDF

27. Increased survival disparities among children and adolescents & young adults with acute myeloid leukemia: A Dutch population‐based study.

Author

Schulpen, Maya, Goemans, Bianca F., Kaspers, Gertjan J. L., Raaijmakers, Marc H. G. P., Zwaan, C. Michel, and Karim‐Kos, Henrike E.

Subjects
ACUTE myeloid leukemia, YOUNG adults, TEENAGERS, SURVIVAL rate, CHILD patients
Abstract

For many cancers, adolescents and young adults (AYAs) have a poorer prognosis than pediatric patients. Our study evaluates survival outcomes of children (0‐17 years) and AYAs (18‐39 years) diagnosed with acute myeloid leukemia (AML) in the Netherlands between 1990 and 2015 (N = 2058) utilizing the population‐based Netherlands Cancer Registry, which includes information on therapy and site of primary treatment. Five‐ and 10‐year relative (disease‐specific) survival were estimated for all patients, children and AYAs. Multivariable analyses were performed using generalized linear models (excess mortality) and logistic regression (early mortality). AYAs with AML had a substantially lower 5‐ and 10‐year relative survival than children (5‐year: 43% vs 58%; 10‐year: 37% vs 51%). The gap in 5‐year relative survival was largest (nearly 20 percent‐points) in 2010 to 2015, despite survival improvements over time across all ages. The multivariable‐adjusted excess risk of dying was 60% higher in AYAs (95% CI: 37%‐86%). Early mortality (death within 30 days of diagnosis) declined over time, and did not differ between children and AYAs. In conclusion, AYAs diagnosed with AML in the Netherlands had a worse prognosis than pediatric patients. The survival gap seemed most pronounced in recent years, suggesting that improvements in care resulting in better outcome for children have not led to equal benefits for AYAs. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

38. Improved survival for adolescents and young adults with Hodgkin lymphoma and continued high survival for children in the Netherlands: a population‐based study during 1990–2015

Author

Reedijk, Ardine M. J., primary, Zijtregtop, Eline A. M., additional, Coebergh, Jan Willem W., additional, Meyer‐Wentrup, Friederike A. G., additional, Hebeda, Konnie M., additional, Zwaan, C. Michel, additional, Janssens, Geert O. R., additional, Pieters, Rob, additional, Plattel, Wouter J., additional, Dinmohamed, Avinash G., additional, Zijlstra, Josée M., additional, Kremer, Leontien C. M., additional, Lugtenburg, Pieternella J., additional, Beishuizen, Auke, additional, and Karim‐Kos, Henrike E., additional

Published
2020
Full Text
View/download PDF

46. Epidemiology of childhood and adolescent cancer in Bangladesh, 2001–2014

Author

Hossain, Mohammad Sorowar, primary, Begum, Mamtaz, additional, Mian, Md Mahmuduzzaman, additional, Ferdous, Shameema, additional, Kabir, Shahinur, additional, Sarker, Humayun Kabir, additional, Karim, Sabina, additional, Choudhury, Salma, additional, Khan, Asaduzzaman, additional, Khan, Zohora Jameela, additional, and Karim-Kos, Henrike E., additional

Published
2016
Full Text
View/download PDF

47. Volwassen kankerpatiënten overleven langer in Nederland: 5-jaarsoverleving 12% toegenomen tussen 1989-1993 en 2004-2008

Author

Siesling, Sabine, Visser, Otto, Luth, Trienika K., Karim-Kos, Henrike E., v.d. Poll-Franse, Lonneke V., Aben, Katja K.H., Damhuis, Ronald A.M., and Faculty of Behavioural, Management and Social Sciences

Subjects
METIS-279455, IR-77769
Abstract

Doel: Inzicht geven in de overleving van kankerpatiënten om verbeteringen in de kankerzorg te kunnen volgen. Opzet: Retrospectieve, bevolkingsbrede cohortstudie. Methode: Voor dit onderzoek werden gegevens van de Nederlandse Kankerregistratie gebruikt. Van alle gediagnosticeerde kankerpatiënten uit de periode 1989-2008 in Nederland werden gegevens over de vitale status verzameld in ziekenhuizen, bevolkingsregisters en de gemeentelijke basisadministratie persoonsgegevens. Per vorm van kanker werden voor de leeftijd gestandaardiseerde relatieve overlevingcijfers berekend. Resultaten: De 5-jaarsoverleving van alle patiënten samen steeg van 47% in 1989-1993 naar 59% in 2004-2008. Bij mannen was de toename in overleving groter dan bij vrouwen, respectievelijk van 40 naar 55% en van 55 naar 62%. Het meest opvallend was de verbetering in overleving bij borst-, prostaat- en darmkanker, waarschijnlijk door oorzaken die voor elk van deze kankersoorten verschillend zijn. Patiënten met chronische myeloïde leukemie lieten een grote overlevingswinst zien (toename: 43%). De overlevingskansen van oudere patiënten waren in het algemeen lager dan die van jongere, vooral bij kanker in het hoofd-halsgebied, eierstokkanker en hematologische maligniteiten. Deze kloof tussen oudere en jongere patiënten is de afgelopen 20 jaar groter geworden. De 10-jaarsoverleving was bij veel kankersoorten niet veel lager dan de 5-jaarsoverleving, behalve bij chronische en indolente hematologische maligniteiten en kanker waarbij terugkeer van de ziekte na langere tijd nog kan plaatsvinden, zoals bij borst- en prostaatkanker. Conclusie: De verbeterde overleving van kankerpatiënten in Nederland, door vroege opsporing en verbeterde behandelingen, kan wijzen op een toenemend aandeel genezen patiënten of op patiënten die langer met kanker leven. Veel winst kan nog behaald worden bij de oudere patiënt. Dit is extra van belang omdat de bevolking vergrijst.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results